Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study.
This randomised, double-blind, multicentric clinical study compared the efficacy and tolerability of the two vaginal antiseptics, 10 mg dequalinium chloride (CAS 522-51-0, Fluomycin N) and 200 mg povidone iodine (CAS 25655-41-8), in a parallel-group design. A total of 180 patients with vaginal infections of varying etiology participated in this study (bacterial vaginosis, fluor vaginalis, vulvo-vaginal candidiasis, trichomoniasis). Patients were randomly allocated to one of the two treatment groups and were treated once per day for 6 days. Control examinations took place 5 to 7 days after the end of treatment, and 3 to 4 weeks after the first control examination. The total symptoms score, a summary score for the clinical symptoms, discharge, burning, pruritus, redness of vulva/vagina, was defined as primary efficacy parameter. The treatments at the first control examination were compared in the full analysis set using the Wilcoxon-Mann-Whitney U-test, 2-sided, thereby proving equivalence of both treatments at the 5% level. Both treatments strongly improved the symptoms of vaginal infections both on short-term and long-term follow-up. Descriptive analysis of the secondary parameters, vaginal pH, degree of purity of the vaginal flora, and number of lactobacilli in the wet mounts, supported the comparable efficacy of both therapies to restore the vaginal milieu. Analysis of the diagnostic subgroups indicated that irrespective of the diagnosis, both treatments improved the efficacy criteria as observed for the entire population. The global assessment of the therapeutic efficacy by investigators and patients supported the results of the efficacy analysis with good to very good ratings in 70-90% of the cases. A good tolerability of both preparations was observed in this study with a low number of adverse events in the test group (5.8%).
Petersen
Eiko E
EE
Albert-Ludwigs-University, Freiburg, Germany.
Weissenbacher
Ernst R
ER
Hengst
Peter
P
Spitzbart
Heinz
H
Weise
Wolfgang
W
Wolff
Friedrich
F
Dreher
Ekkehard
E
Ernst
Uwe
U
Della Casa
Vera
V
Pohlig
Gabriele
G
Graf
Federico
F
Kaiser
R Renato
RR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000382:microbiology; D003868:Dequalinium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008875:Middle Aged; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014245:Trichomonas Infections / Q000188:drug therapy / Q000382:microbiology; D019522:Vaginal Discharge / Q000382:microbiology; D014623:Vaginal Diseases / Q000188:drug therapy* / Q000382:microbiology
D000891:Anti-Infective Agents, Local; D011206:Povidone-Iodine; D003868:Dequalinium